The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Open accessAbstract
BACKGROUND: An association between testosterone therapy (TT) and cardiovascular disease has been reported and TT use is increasing rapidly. METHODS: We conducted a cohort study of the risk of acute non-fatal myocardial infarction (MI) following an initial TT prescription (N = 55,593) in a large health-care database. We compared the incidence rate of MI in the 90 days following the initial prescription (post-prescription interval) with the rate in the one year prior to the initial prescription (pre-prescription interval) (post/pre). We also compared post/pre rates in a cohort of men prescribed phosphodiesterase type 5 inhibitors (PDE5I; sildenafil or tadalafil, N = 167,279), and compared TT prescription post/pre rates with the PDE5I post/pre rates, adjusting for potential confounders using doubly robust estimation. RESULTS: In all subjects, the post/pre-prescription rate ratio (RR) for TT prescription was 1.36 (1.03, 1.81). In men aged 65 years and older, the RR was 2.19 (1.27, 3.77) for TT prescription and 1.15 (0.83, 1.59) for PDE5I, and the ratio of the rate ratios (RRR) for TT prescription relative to PDE5I was 1.90 (1.04, 3.49). The RR for TT prescription increased with age from 0.95 (0.54, 1.67) for men under age 55 years to 3.43 (1.54, 7.56) for those aged ≥ 75 years (p trend = 0.03), while no trend was seen for PDE5I (p trend = 0.18). In men under age 65 years, excess risk was confined to those with a prior history of heart disease, with RRs of 2.90 (1.49, 5.62) for TT prescription and 1.40 (0.91, 2.14) for PDE5I, and a RRR of 2.07 (1.05, 4.11). DISCUSSION: In older men, and in younger men with pre-existing diagnosed heart disease, the risk of MI following initiation of TT prescription is substantially increased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some epidemiological studies have reported an increase in cardiovascular mortality related to TRT while others have not been able to establish a correlation between the two [19,20].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216 · cited 1×
“[26–29] The mechanisms linking estrogens to thrombotic events may be related to markers of activated coagulation, decreased coagulation inhibitors, and activated protein C resistance [30].”
Doubly robust estimation in missing data and causal inference models
Bang, H., & Robins, J. M. (2005) · Biometrics · doi:10.1111/j.1541-0420.2005.00377.x · Cited by 1,998 · cited 1×
“[12] These estimates are unconfounded by the adjustment variables if the prescriptionodds model or the outcome-regression model is specified correctly.”
BackgroundPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · cited 1×
“[26–29] The mechanisms linking estrogens to thrombotic events may be related to markers of activated coagulation, decreased coagulation inhibitors, and activated protein C resistance [30].”
BackgroundAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494 · cited 3×
“[4] This was followed by a meta-analysis of a number of a number of very small trials in predominantly older men which also suggested excess cardiovascular risk.”
BackgroundMethodMajor Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events
Greenland, P. (2003) · JAMA · doi:10.1001/jama.290.7.891 · Cited by 1,053
Hirano, K., & Imbens, G. W. (2001) · Health Services and Outcomes Research Methodology · doi:10.1023/a:1020371312283 · Cited by 1,039 · cited 1×
“[11] This weighting aligns the distribution in the comparison cohort of the variables used in the prescription-probability model to match the distribution in the TT prescription cohort.”
MethodVigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 1×
“[6] In the two studies assessing timing of the increase, it was noted to appear very soon following initiation of therapy.”
BackgroundCardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R. R., Cavazzina, R., Cilloni, D., Stefano, V. D., Elli, E. M., Iurlo, A., Latagliata, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 871 · cited 1×
“Exogenous testosterone (TT) is associated with physiologic changes that predispose to clotting and thrombotic disorders including increased blood pressure [18], polycythemia [19], reductions in HDL cholesterol [18,20], and hyperviscosity of the blood and platelet aggregation.”
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
Thrombotic stroke and myocardial infarction with hormonal contraception
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111840 · Cited by 607 · cited 1×
“[26–29] The mechanisms linking estrogens to thrombotic events may be related to markers of activated coagulation, decreased coagulation inhibitors, and activated protein C resistance [30].”
Background
Flagged first, then by citations
Research works printed but not linked: 1
- Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology. Philadelphia, Pa.; London: Lippincott Williams & Wilkins.
Cited by
Sorted by citations
Items 201–300 of 732
Gao, T., Lin, M., Shao, B., Zhou, Q., Wang, Y., Chen, X., Zhao, D., Dai, X., Shen, C., Cheng, H., et al. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1779471 · Cited by 34
Roles of Testosterone Replacement in Cardiac Ischemia–Reperfusion Injury
Pongkan, W., Chattipakorn, S. C., & Chattipakorn, N. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415587977 · Cited by 34
“On the other hand, several conflicting studies have shown that testosterone replacement also increases the incidence of cardiovascular disease.(33,67,76,78) However, a recent review by Morgentaler et al clarified these controversial studies and concluded that low levels of total testosterone, bioavailable testosterone…”
BackgroundTestosterone Replacement Therapy and Mortality in Older Men
Hackett, G. I. (2015) · Drug Safety · doi:10.1007/s40264-015-0348-y · Cited by 34
“[10] actually chose men initiated on PDE5Is as the ‘‘control’’ group, even though Spitzer et al.”
BackgroundAssociation Between Testosterone Supplementation Therapy and Thrombotic Events in Elderly Men
Ramasamy, R., Scovell, J. M., Mederos, M. A., Ren, R., Jain, L., & Lipshultz, L. I. (2015) · Urology · doi:10.1016/j.urology.2015.03.049 · Cited by 33
Cardiovascular Toxicity of Androgen Deprivation Therapy
Boland, J. L., Choi, W., Lee, M., & Lin, J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01561-9 · Cited by 35
Testosterone, Cardiovascular Risk, and Hormonophobia
Morgentaler, A. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12556 · Cited by 32
Hypogonadism: Easy to define, hard to diagnose, and controversial to treat
Sterling, J., Bernie, A., & Ramasamy, R. (2015) · Canadian Urological Association Journal · doi:10.5489/cuaj.2416 · Cited by 31
Ho, C., Wu, C., Chen, K., Jaw, F.-S., Yu, H., & Liu, S. (2016) · The Aging Male · doi:10.3109/13685538.2015.1129400 · Cited by 32
“studies have reported the opposite effect [15,16].”
Male hormones and men's quality of life
Khera, M. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000256 · Cited by 33
“For the past several years, there has been significant attention turned toward the link between testosterone and cardiovascular disease (CVD) [54].”
BackgroundInfluentialSafety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study
Gittelman, M., Jaffe, J. S., & Kaminetsky, J. C. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.08.013 · Cited by 32
Metabolic syndrome and hypogonadism – two peas in a pod
Ebrahimi, F., & Christ‐Crain, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14283 · Cited by 32
Controversies in testosterone replacement therapy: testosterone and cardiovascular disease
Hwang, K., & Miner, M. M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.146968 · Cited by 31
Trends in Testosterone Prescription and Public Health Concerns
Gabrielsen, J. S., Najari, B. B., Alukal, J. P., & Eisenberg, M. L. (2016) · Urologic Clinics of North America · doi:10.1016/j.ucl.2016.01.010 · Cited by 31
Sesti, F. F., Pofi, R., Minnetti, M., Tenuta, M., Gianfrilli, D., & Isidori, A. M. (2020) · Andrology · doi:10.1111/andr.12876 · Cited by 31
Review of health risks of low testosterone and testosterone administration
Jia, H. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i4.338 · Cited by 33
New horizons in testosterone and the ageing male
Ahern, T., & Wu, F. C. W. (2015) · Age and Ageing · doi:10.1093/ageing/afv007 · Cited by 31
Male hormonal contraception: hope and promise
Piotrowska, K., Wang, C., Swerdloff, R. S., & Liu, P. Y. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00034-6 · Cited by 30
Hsu, B., Cumming, R. G., Naganathan, V., Blyth, F., Couteur, D. G. L., Seibel, M. J., Waite, L. M., & Handelsman, D. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2464 · Cited by 30
Foresta, C., Ferlin, A., Lenzi, A., Montorsi, P., & Italian Study Group on Cardiometabolic Andrology (2017) · Andrology · doi:10.1111/andr.12342 · Cited by 29
“Some controversial reports have been published in last years suggesting possible negative effects of testosterone replacement therapy (TRT) on CV safety (Basaria et al., 2010; Vigen et al., 2013; Finkle et al., 2014).”
BackgroundEMAS position statement: Testosterone replacement therapy in older men
Kanakis, G., Pofi, R., Goulis, D. G., Isidori, A. M., Armeni, E., Erel, C. T., Fistonić, I., Hillard, T., Hirschberg, A. L., Męczekalski, B., et al. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107854 · Cited by 35
“The two retrospective observational studies [120,121] have been strongly criticised [125,126] regarding the short follow-up and the retrospective design (i.e., prescription does not mean consumption), while some authors even asked for retraction [127].”
BackgroundJaiswal, V., Sawhney, A., Nebuwa, C. N., Borra, V., Deb, N., Halder, A., Rajak, K., Jha, M., Wajid, Z., Thachil, R., et al. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.04.001 · Cited by 31
Testosterone recovery therapy targeting dysfunctional Leydig cells
Garza, S., & Papadopoulos, V. (2022) · Andrology · doi:10.1111/andr.13304 · Cited by 28
Guo, W., Bachman, E. S., Vogel, J., Li, M., Peng, L., Pencina, K. M., Serra, C., Sandor, N. L., Jasuja, R., Montano, M. A., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1784 · Cited by 28
Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
Traish, A. M. (2016) · Korean journal of urology · doi:10.4111/icu.2016.57.6.384 · Cited by 28
Role of Testosterone in the Treatment of Cardiovascular Disease
Webb, C. M., & Collins, P. D. (2017) · European Cardiology Review · doi:10.15420/ecr.2017:21:1 · Cited by 31
“Two large observational studies reported an increased risk of adverse outcomes (death, myocardial infarction and stroke) in testosterone-treated men, particularly in men aged >75 years.(55,56) However, the results of these studies have been criticised and must be considered in view of the fact that there was no check…”
BackgroundJasuja, G. K., Ameli, O., Reisman, J. I., Rose, A. J., Miller, D. R., Berlowitz, D. R., & Bhasin, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17141 · Cited by 28
Androgens and the Regulation of Adiposity and Body Fat Distribution in Humans
Tchernof, A., Brochu, D., Maltais‐Payette, I., Mansour, M. F., Marchand, G. B., Carreau, A., & Kapeluto, J. (2018) · Comprehensive physiology · doi:10.1002/j.2040-4603.2018.tb00043.x · Cited by 27
Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.004 · Cited by 27
Testosterone deficiency and cardiovascular mortality
Morgentaler, A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.143248 · Cited by 28
Could androgens be relevant to partly explain why men have lower life expectancy than women?
Schooling, C. M. (2015) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2015-206336 · Cited by 27
“25 Evidence about the effects of androgens from RCTs is limited because the US Institute of Medicine advised, in 2004, that no large scale trials of testosterone should be undertaken until bene fi ts over existing treatments had been established in small trials.”
BackgroundTestosterone deficiency: myth, facts, and controversy.
Miner, M. M., Barkin, J., & Rosenberg, M. T. (2014) · PubMed · Cited by 27
Sansone, A., Rastrelli, G., Cignarelli, A., Ponce, M. D. R., Condorelli, R. A., Giannetta, E., Maseroli, E., Pinto, S., Salzano, C., & Santi, D. (2019) · International Journal of Impotence Research · doi:10.1038/s41443-019-0163-6 · Cited by 27
The association of testosterone with sarcopenia and frailty in chronic liver disease
Chrysavgis, L., Adamantou, M., Angelousi, A. G., & Cholongitas, Ε. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14108 · Cited by 28
Androgen deficiency and type 2 diabetes mellitus
Gibb, F. W., & Strachan, M. W. J. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.04.004 · Cited by 29
Gagliano‐Jucá, T., İçli, T. B., Pencina, K. M., Li, Z., Tapper, J., Huang, G. T.-W., Travison, T. G., Tsitouras, P. D., Harman, S. M., Storer, T. W., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3669 · Cited by 26
“1482 Gagliano-Jucá et al Testosterone Therapy and ECG Parameters in Men J Clin Endocrinol Metab, May 2017, 102(5):1478–1485”
InfluentialJúnior, R. F. R., Ronconi, K. S., de Jesus, I. C. G., Almeida, P., Forechi, L., Vassallo, D. V., Guatimosim, S., Stefanon, I., & Fernandes, A. A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.011 · Cited by 28
Morden, N. E., Woloshin, S., Brooks, C. G., & Schwartz, L. M. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.6505 · Cited by 27
Seftel, A. D. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.11.060 · Cited by 28
An update on the role of testosterone replacement therapy in the management of hypogonadism
Hackett, G. I. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215617648 · Cited by 26
“In another study, Finkle and colleagues retrospectively examined 55,593 insurance claims and compared the incidence of rate of MI in the 1-year prior and 90 days after initial prescription of TRT [Finkle et al. 2014].”
BackgroundEmerging medication for the treatment of male hypogonadism
Aydoğdu, A., & Swerdloff, R. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1226799 · Cited by 25
Role of anabolic testosterone agents and structured exercise to promote recovery in ICU survivors
Wischmeyer, P. E., Suman-Vejas, O. E., Kozar, R. A., Wolf, S. E., Molinger, J., & Pastva, A. M. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000757 · Cited by 25
“One factor potentially limiting wider use of testosterone and its analogues in the ICU has been concern for association of testosterone and increased cardiacvascular and thromboembolic events [51].”
BackgroundTestosterone Replacement Therapy: The Emperor's New Clothes
Sansone, A., Sansone, M., Lenzi, A., & Romanelli, F. (2016) · Rejuvenation Research · doi:10.1089/rej.2016.1818 · Cited by 26
“The fourth and last article, by Finkle et al., 67 was a retrospective analysis of insurance claim data in 55,593 men with information only in regard to diagnosis codes, procedure codes, and prescription data.”
Testosterone Replacement Therapy in Men with Prostate Cancer: A Time-Varying Analysis
Kaplan, A. L., Lenis, A. T., Shah, A., Rajfer, J., & Hu, J. C. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12768 · Cited by 26
Huang, G., Travison, T., Maggio, M., Edwards, R. R., & Basaria, S. (2016) · Clinical Endocrinology · doi:10.1111/cen.13049 · Cited by 26
Miller, C., Madden-Doyle, L., Jayasena, C. N., McIlroy, M., Sherlock, M., & O’Reilly, M. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae128 · Cited by 27
Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism
Bhasin, S., & Snyder, P. J. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2404637 · Cited by 27
Testosterone, thrombophilia, thrombosis
Glueck, C. J., Friedman, J., Hafeez, A., Hassan, A., & Wang, P. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000126 · Cited by 25
Livingston, M. A., Downie, P., Hackett, G. I., Marrington, R., Heald, A. H., & Ramachandran, S. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13607 · Cited by 25
Testosterone therapy and mortality risk
Eisenberg, M. L., Li, S., Herder, D., Lamb, D. J., & Lipshultz, L. I. (2014) · International Journal of Impotence Research · doi:10.1038/ijir.2014.29 · Cited by 25
Wu, B. W., Lorezanza, D., Badash, I., Berger, M., Lane, C. J., Sum, J. C., Hatch, G. F. R., & Schroeder, E. T. (2017) · Orthopaedic Journal of Sports Medicine · doi:10.1177/2325967117722794 · Cited by 25
“were primarily administered to hypogonadal men.(15,55) Other studies in healthy young men have found no significant adverse events from testosterone supplementation below 600 mg/wk.”
BackgroundSerum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study
Rosenberg, M. A., Shores, M. M., Matsumoto, A. M., Bůžková, P., Lange, L. A., Kronmal, R. A., Heckbert, S. R., & Mukamal, K. J. (2018) · Clinical Cardiology · doi:10.1002/clc.22965 · Cited by 27
Corona, G., Rastrelli, G., Sparano, C., Carinci, V., Casella, G., Vignozzi, L., Sforza, A., & Maggi, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2337741 · Cited by 26
“The FDA’s position on possible CV risk associated with TRT was essentially based on three studies published almost 10 years ago [17–19].”
BackgroundImpact of recent FDA ruling on testosterone replacement therapy (TRT)
Metzger, S., & Burnett, A. L. “. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.09.08 · Cited by 24
“Limitations of the study included a lack of knowledge of the indications for TRT prescription within the cohorts, testosterone doses consumed and demographic data (12).”
BackgroundLapauw, B., & Kaufman, J. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0394 · Cited by 24
Shores, M. M., Walsh, T. J., Korpak, A. M., Krakauer, C. A., Forsberg, C. W., Fox, A., Moore, K. P., Heckbert, S. R., Thompson, M. L., Smith, N. L., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020562 · Cited by 25
Cannarella, R., Gusmano, C., Leanza, C., Garofalo, V., Crafa, A., Barbagallo, F., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2023) · Asian Journal of Andrology · doi:10.4103/aja202352 · Cited by 27
“7 Similarly, in a parallel-group, randomized, placebo-controlled, double-blind trial conducted on 209 patients, Basaria et al. 28 found more CV-related adverse events in patients receiving T than in the placebo group.”
Testosterone therapy and prostate cancer—safety concerns are well founded
Klotz, L. H. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2014.338 · Cited by 24
Zhao, J. V., & Schooling, C. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.174 · Cited by 24
Ghimire, A., Bisset, E. S., & Howlett, S. E. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0256-4 · Cited by 24
Obesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk
Singh, P., Covassin, N., Marlatt, K. L., Gadde, K. M., & Heymsfield, S. B. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210014 · Cited by 44
Park, M. G., Cho, D.-Y., Yeo, J. K., Cho, S. I., Jung, J., Yang, S., Kong, D.-H., Ha, J. K., & Kim, J.-D. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.184269 · Cited by 23
Traish, A. M. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00174.2016 · Cited by 23
Testosterone therapy and prostate cancer
Pastuszak, A. W., Rodríguez, K. M. G., Nguyen, T. M., & Khera, M. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.08.17 · Cited by 23
“Most recently, a handful of studies have observed a positive correlation between testosterone levels and CV events, especially in older men, and have ultimately led to changes in testosterone labeling (18-21).”
BackgroundMale hypogonadism: therapeutic choices and pharmacological management
Vignera, S. L., Izzo, G., Emerenziani, G. P., Cannarella, R., Condorelli, R. A., Calogero, A. E., & Aversa, A. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03195-8 · Cited by 24
Leydig cell aging: Molecular mechanisms and treatments
Papadopoulos, V., & Zirkin, B. R. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2020.12.023 · Cited by 24
Grossmann, M., Anawalt, B. D., & Wu, F. C. W. (2014) · Clinical Endocrinology · doi:10.1111/cen.12594 · Cited by 23
Elsherbiny, A., Tricomi, M., Bhatt, D., & Dandapantula, H. K. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0838-x · Cited by 23
Yatsu, T., Kusakabe, T., Kato, K., Inouye, Y., Nemoto, K., & Kanno, Y. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00748 · Cited by 26
Miner, M. M., Morgentaler, A., Khera, M., & Traish, A. M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13589 · Cited by 23
Finkelstein, J. S., Lee, H., Burnett‐Bowie, S. M., Darakananda, K., Gentile, E. C., Goldstein, D. W., Prizand, S. H., Krivicich, L. M., Taylor, A. P., Wulczyn, K. E., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa318 · Cited by 23
Syed, A. A. S., He, L., & Shi, Y. (2020) · Genes · doi:10.3390/genes11070721 · Cited by 25
Irrational Exuberance in Testosterone Prescribing: When Will the Bubble Burst?
Handelsman, D. J. (2015) · Medical Care · doi:10.1097/mlr.0000000000000416 · Cited by 22
Testosterone Therapy Among Prostate Cancer Survivors
Nguyen, T. M., & Pastuszak, A. W. (2016) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2016.06.005 · Cited by 22
Sexuality and Quality of Life in Aging: Implications for Practice
Buttaro, T. M., Koeniger‐Donohue, R., & Hawkins, J. W. (2014) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.04.008 · Cited by 22
Late onset hypogonadism of men is not equivalent to the menopause
Saad, F., & Gooren, L. J. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.06.016 · Cited by 22
Donner, D. G., Elliott, G. E., Beck, B. R., Bulmer, A. C., & Toit, E. F. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138019 · Cited by 22
“Conversely, more recent work has identified an increased risk of myocardial infarction within 90 days of initiating testosterone replacement therapy (TRT) [90].”
BackgroundDias, J. P., Shardell, M. D., Carlson, O. D., Melvin, D., Caturegli, G., Ferrucci, L., Chia, C. W., Egan, J. M., & Basaria, S. (2017) · Andrology · doi:10.1111/andr.12284 · Cited by 22
“Recent reports have raised concerns regarding cardiovascular adverse effects of testosterone therapy in older men (He et al., 2013; Vigen et al., 2013; Xu et al., 2013; Finkle et al., 2014; Layton et al., 2015).”
BackgroundInfluentialRais, M., Wilson, R. M., Urbanski, H. F., & Messaoudi, I. (2017) · GeroScience · doi:10.1007/s11357-017-9979-5 · Cited by 22
Testosterone, frailty and physical function in older men
Hsu, B., Cumming, R. G., & Handelsman, D. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1475227 · Cited by 22
“studies have also reported increased risks of mortality, myocardial infarction and ischemic stroke with the use of T therapy [79,80].”
BackgroundThe Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Kırlangıç, O. F., Yilmaz‐Oral, D., Kaya‐Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., Khanam, A., Öztekin, Ç. V., & Gür, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2020.02.006 · Cited by 23
“Although TRT in a physiological dose improved left ventricular function, some studies reported that it increased the risk of myocardial infarction in men with preexisting heart disease and hypogonadism, respectively.(66,67) Low-dose TRT combined with vildagliptin (dipeptidyl peptidase 4 inhibitor) which increases the…”
BackgroundWu, J., Hadoke, P. W. F., Mair, I., Lim, W. G., Miller, E., Denvir, M. A., & Smith, L. B. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu142 · Cited by 21
Association between serum levels of testosterone and biomarkers of subclinical atherosclerosis
Rezanezhad, B., Borgquist, R., Willenheimer, R. B., & Elzanaty, S. (2017) · The Aging Male · doi:10.1080/13685538.2017.1412422 · Cited by 21
Kozloski, M., Schumm, L. P., & McClintock, M. K. (2014) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbu123 · Cited by 20
“, 2010), but such physical improvements have come with increased rates of adverse cardiovascular events (including myocardial infarctions, heart failure, and stroke), adverse respiratory events, and adverse dermatological events (Basaria et al., 2010; Bhasin et al., 2010; Finkle et al., 2014; Vigen et al., 2013).”
BackgroundTestosterone therapy in the new era of Food and Drug Administration oversight
Desroches, B. R., Kohn, T. P., Welliver, C., & Pastuszak, A. W. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.03.13 · Cited by 21
“In 2014, two observational studies that both suggested an increased CV risk in men who received testosterone prescriptions prompted the FDA to further evaluate the safety of testosterone (5,6).”
BackgroundHassan, J., & Barkin, J. (2016) · PubMed · Cited by 21
Effects of testosterone and progressive resistance exercise on vascular function in older men
Hildreth, K. L., Schwartz, R. S., Griend, J. P. V., Kohrt, W. M., Blatchford, P. J., & Moreau, K. L. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00165.2018 · Cited by 21
“Although large, long-term controlled trials evaluating the effects of T treatment on cardiovascular outcomes are lacking, several studies have reported increased adverse cardiovascular events associated with T treatment (5, 13, 38).”
BackgroundBig Data: transforming drug development and health policy decision making
Alemayehu, D., & Berger, M. L. (2016) · Health Services and Outcomes Research Methodology · doi:10.1007/s10742-016-0144-x · Cited by 21
“Since RCTs used for registration purposes are typically underpowered to reveal safety signals for rare events, there is a lot of focus on evidence generated based on observational data (Finkle et al. 2014).”
BackgroundJasuja, G. K., & Rose, A. J. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4113-z · Cited by 19
Testosterone replacement in men with sexual dysfunction
Lee, H., Hwang, E. C., Oh, C. K., Lee, S., Yu, H. S., Lim, J. S., Kim, H. W., Walsh, T. J., Kim, M. H., Jung, J. H., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013071.pub2 · Cited by 20
Sullivan, S. D., Nash, M. S., Tefara, E., Tinsley, E. A., & Groah, S. L. (2017) · PM&R · doi:10.1016/j.pmrj.2017.08.404 · Cited by 21
“However, other studies in non-SCI populations inform the potential risks of TRT, particularly increased risk of cardiovascular-related adverse events such as myocardial infarction [42,43].”
BackgroundOpioid-Induced Hypogonadism in the United States
Baillargeon, J., Raji, M. A., Urban, R. J., López, D. S., Williams, S. B., Westra, J. R., & Kuo, Y. (2019) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2019.06.007 · Cited by 20
“It is possible that this finding reflects some clinicians’ concerns about conflicting reports regarding adverse cardiovascular effects associated with testosterone therapy.(32-36) The results of our study may have been influenced by the several limitations.”
ResultTestosterone Replacement Therapy in Orthopaedic Surgery
Cohn, R. M., Ganz, M. P., & Scuderi, G. R. (2024) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-23-00348 · Cited by 19
“garnering concern depicted an increase in 8 ----- © American Academy nonfatal myocardial infarction within the first 90 days of initiation of TRT, but paradoxically displayed a decrease in event risk after the initial 90-day period.”
BackgroundMarcelli, M., & Mediwala, S. N. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001233 · Cited by 23
Gore, A. C., Hall, J. E., & Hayes, F. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00037-5 · Cited by 19
Wu, Y., & Sung, W. (2024) · Pharmaceuticals · doi:10.3390/ph17091233 · Cited by 19
“Two observational studies [22,23] demonstrated that TRT increased cardiovascular risk, which was confirmed by a meta-analysis of randomized trials [21].”
BackgroundTestosterone stimulates cholesterol clearance from human macrophages by activating LXRα
Kilby, E., Kelly, D. M., & Jones, T. H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119040 · Cited by 17
Relationships between endogenous and exogenous testosterone and cardiovascular disease in men
Thirumalai, A., & Anawalt, B. D. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09752-7 · Cited by 20
Zhao, H., Li, J., Li, Z., Zhang, Q., Zhong, M.-K., Yan, M., & Qiu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182113 · Cited by 19
“However, the necessity of testosterone treatment (TT), especially the association between TRT and major adverse cardiovascular events (MACEs) remains controversial.”
MethodInfluentialTraish, A. M. (2023) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qead031 · Cited by 18
Testosterone therapy and cardiovascular risk
Walsh, J. P., & Kitchens, A. C. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.10.014 · Cited by 19
“Safety concerns about testosterone came to the forefront after the recent publication of two observational studies suggesting associations of testosterone therapy with adverse CV outcomes [7,8].”
Background
Metadata
- Authors
- Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N.
- Affiliations
- University of California, Los Angeles (US)
- National Cancer Institute (US)
- Corresponding author
- Finkle, William D.
- Hoover, Robert N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-29
- Volume
- 9
- Issue
- 1
- Pages
- e85805
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3905977
- OpenAlex
- W2156204904
- Cited by
- 735
- References
- 31
- Citations by year
- 2026: 21 · 2025: 34 · 2024: 33 · 2023: 42 · 2022: 45 · 2021: 32 · 2020: 41 · 2019: 52 · 2018: 69 · 2017: 87 · 2016: 79 · 2015: 112 · 2014: 86
- FWCI
- 97.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, public-domain)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, myocardial infarction, cardiovascular risk, phosphodiesterase-5 inhibitors, sildenafil, tadalafil, men, older men, heart disease history, drug safety, adverse drug reactions
- MeSH terms
- Tadalafil, Sildenafil Citrate, Age Factors, Aged, Carbolines, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Purines, Risk, Sulfones, Testosterone, Prescription Drugs, Phosphodiesterase 5 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
